Alkylation of cyclic amines with alcohols catalyzed by Ru(II) complexes bearing N -Heterocyclic carbenes
作者:Öznur Doğan Ulu、Nevin Gürbüz、İsmail Özdemir
DOI:10.1016/j.tet.2017.09.027
日期:2018.2
includes the synthesis of 2-(1,3-dioxane-2-yl)ethyl substituted benzimidazole substituted N-heterocyclic carbenes precursors and their ruthenium complexes. Synthesized compounds were characterized by elemental analysis and NMR spectroscopy. All complexes have been tested in the alkylation of pyrrolidine and morpholine with alcohols, showing an excellent activity in this reaction.
NHC–Ag complex derived from N -(1-naphthalenylmethyl)-substituted benzimidazolium salt L12 , affording the corresponding alcohol in 92% yield and with 92% ee. Moreover, the evaluation of an Ir catalyst precursor showed that cationic [Ir(cod) 2 ]BF 4 complex could be used. Furthermore, the introduction of a chiral hydroxyamide side arm into the benzimidazolium salt was critical for the successful design of
novel benzimidazolium salts (1-4) and their pyridine enhanced precatalyst preparation stabilization and initiation (PEPPSI) themed palladium N-heterocyclic carbene complexes [PdCl2(NHC)(Py)] (5-8), where NHC = 1-(N-methylphthalimide)-3-alkylbenzimidazolin-2-ylidene and Py = 3-chloropyridine, were synthesized and characterized by means of (1)H and (13)C(1)H} NMR, UV-vis (for 5-8), ESI-FTICR-MS (for 2
1,3-Dioxane Functionalized Pd-PEPPSI Catalyst for Direct Arylation of Heteroaromatics
作者:Öznur Doğan Ulu
DOI:10.1016/j.molstruc.2021.131202
日期:2021.12
(pyridine-enhanced precatalyst preparation, stabilization, and initiation) (2a-d) were prepared to catalyze the direct arylation of heteroaromatics (2-acetylthiophene and 2-furaldehyde) with various aryl bromides. The structures of all isolated compounds were elucidated based on spectroscopic methods (1H and 13C NMR, FT-IR and LC-MS spectroscopy). Under optimized reaction conditions, C5-arylated products
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases
作者:Ulrike E. Hille、Christina Zimmer、Carsten A. Vock、Rolf W. Hartmann
DOI:10.1021/ml100071j
日期:2011.1.13
concept, we succeeded in the development of a series of highly active and selectiveinhibitors of CYP11B1, the key enzyme of cortisol biosynthesis, as potential drugs for the treatment of Cushing's syndrome and related diseases. Thus, compound 33 (IC50 = 152 nM) is the first CYP11B1inhibitor showing a rather good selectivity toward the most important steroidogenic CYP enzymes aldosterone synthase (CYP11B2)